Selvigaltin (GB1211), an orally offered small molecule galectin-three inhibitor created to be a remedy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Desk 4 Statistical evaluation of dose proportionality of the pharmacokinetic parameters of GB1211 https://selvigaltin-gb121113567.bloggerswise.com/47325367/selvigaltin-an-overview